
Sara Tolaney/X
Aug 29, 2025, 15:00
Sara Tolaney Leads A012103 Trial to Compare Pembrolizumab to Observation in TNBC
Alliance for Clinical Trials in Oncology shared a post on X:
”Sara Tolaney leads Alliance for Clinical Trials in Oncology A012103 to compare the effect of pembrolizumab to observation in pts with triple-negative breast cancer who had a pathologic complete response after chemotherapy plus pembrolizumab.”
Learn more here.
Sarah Sammons, Breast Medical Oncologist at Dana-Farber Cancer Institute, shared a post by Alliance for Clinical Trials in Oncology on X, adding:
”We don’t know if TNBC patients who have pCR after Keynote 522 really benefit from 9 more cycles of pembro.
This trial will answer.”
More posts featuring Sarah Sammons.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 29, 2025, 14:44
Aug 29, 2025, 14:31
Aug 29, 2025, 14:23
Aug 29, 2025, 14:17
Aug 29, 2025, 14:13
Aug 29, 2025, 14:09